CureVac (CVAC)
(Delayed Data from NSDQ)
$3.68 USD
-0.11 (-2.90%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $3.68 0.00 (0.00%) 5:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CVAC 3.68 -0.11(-2.90%)
Will CVAC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CVAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CVAC
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
CVAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
Moderna (MRNA) Secures BARDA Funding for Bird Flu Vaccine
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Other News for CVAC
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Quest Diagnostics, Southwest Airlines rise; Simulations Plus falls, Wednesday, 7/3/2024
TOP NEWS: GSK inks licensing deal with CureVac for flu and Covid drugs
CureVac Shareholders Approve Key Resolutions
Bird flu shots to begin in Finland